Month: April 2020

Dr. Chow to work with Draganfly to implement the Vital Intelligence camera and drone technology in the United States to combat COVID-19 (Coronavirus)Vancouver, British Columbia, April 08, 2020 (GLOBE NEWSWIRE) — Draganfly Inc. (CSE: DFLY) (OTCQB: DFLYF) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading manufacturer within the commercial Unmanned Aerial Vehicle (“UAV”), Remotely Piloted Aircraft Systems (“RPAS”), and unmanned vehicle sector (“UVS”), today announced that its Board of Directors has appointed Dr. Jack C. Chow as an advisory member to its Board.Draganfly announced on March 26, 2020 that it had been selected as the exclusive global systems integrator for the Vital Intelligence Project a healthcare data services & deep learning company in conjunction with the University of South Australia,...

EDEN PRAIRIE, Minn., April 08, 2020 (GLOBE NEWSWIRE) — CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced the company will host an interactive, clinician-led webinar to discuss cardio-pulmonary-renal management in real-world COVID-19 patients. Dr. Daniel J. Goldstein, Professor & Vice Chairman, Department of Cardiothoracic Surgery, Montefiore Medical Center, New York will moderate the online discussion on Friday, April 10 at 1:00 p.m. EDT.Clinicians will present COVID-19 Case Studies in a grand rounds format and discuss:Complex fluid balance and fluid overload managementStrategies for managing cardio-pulmonary status and hemodynamic stateManaging the continuum of acute kidney injury (AKI) through end-stage renal disease (ESRD)Current...

Thorofare, New Jersey, April 08, 2020 (GLOBE NEWSWIRE) — Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that its collaboration with Premas Biotech has successfully completed a second milestone, the successful expression of the three coronavirus antigens, Spike (S), Envelope (E), and Membrane (M), that were selected for their vaccine candidate. The antigens have been expressed using the D-CryptTM platform at Premas Biotech, which utilizes its vectors and S cerevisiae strain. Premas is now moving forward with purification and post-expression processing, which we believe should lead to a scaling up of the antigens.Prabuddha Kundu, Co-Founder and Managing Director at Premas Biotech, commented, “We are happy to announce our success in expressing all three...

TORONTO, April 08, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, is pleased to announce that the Company has retained Novotech, the largest biotech clinical research organization (“CRO”) specialist in the Asia-Pacific region, to serve as the Company’s CRO to pursue future human clinical studies for Bucillamine in the treatment of infectious diseases, including the coronavirus disease (“COVID-19”) in Asia-Pacific Countries (“APAC”).“We are pleased to have Novotech as part of our team to support us in our global clinical strategy for Bucillamine in infectious diseases, which includes COVID-19, and they will work in parallel and complement our initiatives in the U.S.,...

Creates CISO Council and Advisory Board Names Alex Stamos As Advisor CEO Eric Yuan to Host First Weekly Webinar Wednesday, April 8SAN JOSE, Calif., April 08, 2020 (GLOBE NEWSWIRE) — Zoom Video Communications, Inc. (NASDAQ: ZM) today published a blog post by founder and CEO Eric Yuan with an update on its 90-day plan to better identify, address, and fix issues proactively and improve the safety, privacy, and security of Zoom’s platform. This update includes the creation of a CISO Council and Advisory Board and the hiring of Alex Stamos, former Chief Security Officer of Facebook, as an outside advisor.The Company will also be hosting its first weekly webinar led by Eric Yuan on April 8, 2020 at 10am PT to provide privacy and security updates to its community and address community questions live.The full text of the blog post is as...

ATHENS, Greece, April 08, 2020 (GLOBE NEWSWIRE) — Performance Shipping Inc. (NASDAQ: PSHG), (the “Company”), a global shipping company specializing in the ownership of vessels, today announced that it has repurchased and cancelled all of its 400 remaining issued and outstanding Series B-2 Preferred Convertible Shares from an unaffiliated third party at their stated value of $1,000 per share.  Prior to their cancellation, the Series B-2 Preferred Shares entitled their holder to convert each of their Series B-2 Preferred Share into common shares of the Company at a conversion price equal to a discounted volume weighted average price of the Company’s common shares.  Commenting on the repurchase and cancellation of the Series B-2 Preferred Convertible Shares, Mr. Andreas Michalopoulos, the Company’s Deputy Chief Executive Officer, stated:“The...

As provided in Section XI ‘Calculation of the Net Asset Value’ of the Articles of Association of INVL Technology, the net asset value of the Company was EUR 28,958,136.53 or EUR 2.3784 per share on 31 December 2019.The person authorized to provide additional information:Kazimieras TonkūnasINVL Technology Managing PartnerE-mail k.tonkunas@invltechnology.lt

Atsižvelgiant į SUTPKIB „INVL Technology“ įstatų XI skyrių „Grynųjų aktyvų vertės skaičiavimas“, skelbiama bendrovės grynųjų aktyvų vertė 2019 m. gruodžio 31 d. yra 28 958 136,53 eurai arba 2,3784 euro akcijai.Asmuo, įgaliotas suteikti papildomą informaciją:Kazimieras TonkūnasUTIB „INVL Technology“ vadovaujantysis partnerisEl. paštas k.tonkunas@invltechnology.lt

As of 31 December 2019, INVL Technology’s equity amounted to EUR 28.96 million or EUR 2.38 per share.The net audited profit of the company in 2019 amounted to EUR 933 thousand.Additional information:The equity of INVL Technology, a company that invests in IT businesses, was EUR 29 million at the end of 2019, or EUR 2.38 per share. The latter figure increased 3.3% during the year. The value of the company’s financial assets at the end of the reporting period was EUR 25.9 million and increased EUR 1.7 million during the year. Audited net profit for 2019, including revaluation of financial assets, was EUR 0.9 million, and compared with 2018 decreased 77.9%.The aggregated revenues of the businesses INVL Technology owns increased 6% in 2019 to EUR 34.5 million (from EUR 32.6 million in 2018), while aggregate EBITDA was EUR 2.26 million...